Skip to main content

Table 1 Participant characteristics

From: The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease

  AERD [n = 240] ATA
[n = 226]
Control
[n = 71]
p-value
(ANOVA)
T-Test
Demographics
 Age (yrs) 49.3 [0.8] 49.7 [1.0] 44.3 [1.6] 0.008  
 Gender [M/F] 74/166 68/158 35/36 0.007  
 BMI (kg/m2) 26.7 [0.3] 27.1 [0.4] 25.6 [1.0]   
 Duration of asthma (yrs) 18.8 [0.8] 15.2 [1.0] n/a   < 0.0001
 ACT; uncontrolled, n [%] 108 [46] 98 [46] n/a   
 Medication use
  High dose ICS/Oral CS, n (%) 63 (26) 37 (18) n/a   0.03
  High dose ICS > 500 (μg/d), n (%) 62 (26) 52 (25.5) n/a   
  Low dose ICS ≤500 (μg/d), n (%) 78 (33) 92 (44.7) n/a   0.008
  No ICS or Oral CS, n (%) 3 (14) 25 (12.4) n/a   
Lung functions
 FEV1% predicted 79.8 [1.3] 86.6 [1.4] n/a   0.0003
 FEV1 %FVC 68.8 [0.7] 74.8 [0.7] n/a   < 0.0001
  1. Mean (SEM); Definition of abbreviations: AERD Aspirin-Exacerbated Respiratory Disease, ATA Aspirin Tolerant Asthma, M Male, F Female, BMI Body mass index, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, CS Corticosteroidsm, ICS Inhaled Corticosteroids